Fig. 1From: HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia—rationale, study design and protocolHORNBILL trial design. AE, adverse event; BCVA, best-corrected visual acuity; D, day; FAZ, foveal avascular zone; MD, multiple dose; MTD, maximum tolerated dose; SRD, single rising dose; W, weekBack to article page